IM

IM Therapeutics is a clinical-stage biotechnology company focused on developing personalized small molecule therapies for autoimmune diseases by targeting specific Human Leukocyte Antigen (HLA) variants. The company's lead program, IMT-002, is a first-in-class oral small molecule designed to block the HLA-DQ8 protein, a major genetic risk factor for Type 1 diabetes, to prevent the immune system from attacking insulin-producing beta cells. By utilizing a structure-based drug design platform, IM Therapeutics aims to create highly selective therapies that modulate the immune response without broad immunosuppression. The company is also expanding its pipeline to target other HLA-linked conditions, such as celiac disease.